Milevoni (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Milevoni, is a combined oral contraceptive presented as a tablet for oral use. It is used to prevent pregnancy in women of reproductive age. GNH USA supplies Milevoni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milevoni, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Prevention of pregnancy: provides reliable contraceptive protection for women of reproductive age. Regulation of menstrual cycle: helps to stabilize bleeding patterns and reduce menstrual discomfort. Treatment of acne: reduces androgen‑driven skin lesions in women when prescribed for this indication.

Milevoni may cause a range of adverse reactions.

Common Side Effects: - Nausea or gastrointestinal upset. - Breast tenderness or enlargement. - Headache or migraine. - Spotting or breakthrough bleeding. - Weight gain or fluid retention. - Mood changes or irritability.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism. - Arterial thrombosis leading to stroke or myocardial infarction. - Severe allergic reaction (anaphylaxis). - Hepatic dysfunction or jaundice. - Hyperglycemia in diabetic patients. - Visual disturbances or eye pain.

Before prescribing Milevoni, clinicians should consider several safety factors.

Assess thrombotic risk: evaluate personal or family history of clotting disorders. Avoid smoking: especially in women over 35 years of age. Review liver function: contraindicated in severe hepatic disease. Consider drug interactions: check concomitant medications that affect estrogen metabolism. Pregnancy category: contraindicated in pregnancy (Category X). Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Milevoni can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy. - Certain antiretrovirals (e.g., efavirenz): can lower hormone levels and increase risk of unintended pregnancy. - Additional estrogen‑containing therapies: increase risk of thrombotic events.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: may slightly diminish absorption. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure as hormonal changes can affect control. - Herbal supplements like St. John’s wort: may decrease hormonal effectiveness, requiring additional contraceptive measures.